SRNE Stock Recent News
SRNE LATEST HEADLINES
ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17, 2022 at 11:30 AM EST.
Sorrento Therapeutics has been in the limelight for all the wrong reasons. Its R&D is just a byproduct of its business.
When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful.
The drugmaker's stock is moving upward today in sympathy with the broader biopharmaceutical industry.
Sorrento's financials are not helping it in the current down market.
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and members of Sorrento's executive team will participate the 20th Annual Morgan Stanley Global Healthcare Conference:
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
An FDA fast track designation for a high-value product candidate is powering the biotech's shares higher today.
Source: Bukhta Yurii / Shutterstock.com Sorrento Therapeutics (NASDAQ: SRNE ) stock is getting a boost on Wednesday after the FDA granted it fast-track designation for SP-103. SP-103 is Sorrento Therapeutics' “non-opioid triple-strength, non-aqueous lidocaine topical system for the treatment of acute LBP.
Biopharmaceutical outfit Sorrento Therapeutics (US:SRNE) rallied +6.2% on Tuesday and extended gains by a further +2.1% in post market trading after the company released positive trial results cnx.cmd.push(function() {var videoId = decodeURIComponent(""); cnx({ playerId: "0a52d238-33b5-4c04-ba5e-323e192cfbe8", mediaId: videoId}).render("b8b49474e42e4a61905a1353db504ac9"); }); from Abivertinib that was used for the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).